
Elekta and BMS partner for digital treatment for melanoma
Betsy Goodfellow | December 19, 2023 | News story | Research and Development | BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution for patients with melanoma, utilising Elekta’s digital health interventions platform, Kaiku Health.
The solution is intended to provide an “accessible, user-friendly way for patients to share relevant information on their wellbeing with their care team, and to receive tailored support and guidance during treatment,” according to the company’s press release.
It will utilise machine learning (ML) algorithms and is intended to allow real-time evaluation of patient-reported data, giving healthcare providers personalised insights with the hope of improving patients’ care pathways and experiences.
The digital solution will utilise personalised symptom monitoring, allowing healthcare professionals to react earlier and focus on the important information.
Anish Patankar, senior vice president and head of Business Line Software at Elekta, commented: “We are thrilled to collaborate with Bristol Myers Squibb to potentially advance the use of digital health interventions, such as in the treatment of melanoma. By providing patients with the tools and support they need, we aim to empower them to actively participate in their treatment journey.”
Betsy Goodfellow
Related Content

Five facts about UV exposure and sun safety
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s …

Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise …






